GPT and metabolic syndrome: A systematic review and meta-analysis revealed that the baseline circulating ALT level is associated with the risk of MetS and exhibits a linear dose-response relationship [14], which was identical to the results of a cross-sectional study including over 15000 adults and a longitudinal study with 7 years of follow-up from China [12, 13].